1,183 patients with colon cancer were compared while on either a combination of the Amgen Inc. drug, Vectibix [panitumumab] and a chemotherapy regimen, called Folfox, to chemotherapy alone in the late stage trial. The company said that the Vectibix group had greater progression-free survival, a measurement of how long they lived until their disease began to advance or spread again. The drug is currently approved as a third line treatment.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지